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Abstract 
Cascade testing or screening provides an important mechanism for identifying people at risk of 
a genetic condition. For some autosomal dominant conditions, such as Familial 
Hpercholesterolaemia (FH), identifying relatives allows for significant health-affecting 
interventions to be administered, which can extend a person’s life expectancy significantly. 
However, cascade screening is not without ethical implications. In this paper, we examine one 
ethically contentious aspect of cascade screening programmes, namely the alternative 
methods by which relatives of a proband can be contacted. Should the proband be responsible 
for contacting his or her family members, or should the screening programme contact family 
members directly? We argue that direct contact is an ethically justifiable method of contact 
tracing in cascade screening for FH. Not only has this method of contact already been utilised 
without adverse effects, an examination of the ethical arguments against it shows these are 
unsubstantiated. We describe several criteria which, if met, will allow an appropriate balance 
to be struck between maximising the efficiency of family tracing and respecting the interests of 
probands and their relatives. 
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Introduction 
Familial Hypercholesterolaemia (FH) Cascade Screening 
An autosomal dominant condition, FH is primarily caused by mutations in the low density 
lipoprotein receptor (LDLR) gene.1,2 If left untreated, FH leads to substantially elevated serum 
cholesterol concentrations and a more than 50% risk of coronary heart disease (CHD) by age 
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50 in men and at least 30% in women by age 60.3 With an estimated prevalence of 1 in 500, 
approximately 110 000 people in the United Kingdom are thought to have FH, although at least 
75% of this group remain undiagnosed.4 Preventative treatment with HMG-CoA reductase 
inhibitors (statins), in combination with a healthy lifestyle, is effective in delaying or preventing 
the onset of coronary heart disease.5,6 Effective primary prevention, however, requires early 
diagnosis. 
Diagnosis of FH is based on the presence of elevated of plasma total and low density 
lipoprotein cholesterol, plus clinically detected stigmata and a family history of either early 
CHD or elevated lipid levels. An unequivocal diagnosis can also be made by the carriage of a 
pathogenic LDLR mutation, identified by a DNA-based test.7 The utility of DNA testing remains 
limited however, as a mutation is currently identified in only 30-60% of clinically identified 
cases.8 
Despite these potential difficulties, a recent modelling exercise and review have suggested 
that cascade testing based on lipid or genetic testing in the relatives of known FH probands is 
cost effective in terms of life-years gained.8,9 Further, a Netherlands-based DNA testing 
programme has been running for more than five years,10 with good recruitment rates and 
reported patient satisfaction.11 
Policy support in light of this clinical effectiveness was demonstrated by the United Kingdom 
Government in its 2003 White Paper on Genetics, where a commitment to pilot cascade 
testing for FH was made.12 The two-year programme will identify new cases from the relatives 
of FH patients already attending lipid clinics, with the aim of finding two new FH patients for 
every known proband. The pilot will also address whether cascade testing (based on 
measurement of plasma lipid levels) is acceptable, feasible and cost effective within the 
current organisation of the NHS and contemporary social structures. It will also consider 
whether different approaches to cascade testing are warranted in different social groups, and 
will delineate the education and training requirements for national implementation. 
It is important to recognise that undertaking cascade screening for a genetic condition by 
measuring a plasma trait, as opposed to using a DNA test, does not mean that concerns 
typically associated with genetic testing are avoided. A person’s test result will still have 
implications for his or her family members, and may affect life planning, employment or one’s 
ability to obtain life insurance.13 However, existing cascade screening programmes for FH have 
shown little, if any, long-term detrimental effects upon participants’ quality of life.11,14,15 
 
Relative contact in Cascade Testing 
Cascade testing provides one method for identifying relatives at risk of a particular heritable 
condition. Once an affected proband is recognised, his or her first (or second) degree relatives 
are systematically identified, contacted and offered information, after which they can decide 
whether to undergo testing. For FH, targeted cascade screening will provide a greater rate of 
case identification than general population screening.8,9 
The success of cascade screening programs is dependent on a high pickup rate from the tracing 
of a proband’s first and second-degree family members (‘contact tracing’), both of which 
depend on information being reported by the proband.16 Broadly, two alternative methods can 
be used to establish contact with a proband’s relatives. These are family contact, which 
involves providing information and clinic contact details to the proband, who will then pass 
this on to his or her relatives (also called “proband initiated contact”17); and direct contact, 
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where probands are invited to provide the clinic with relatives’ names and contact details, so 
the clinic can contact them directly. 
Both methods of contact tracing raise ethical and legal issues. In particular, there is an ethical 
tension between maximising the utility of cascade screening and respecting the interests of 
probands and their relatives. Clinicians have an obligation to protect the confidentiality of the 
proband, but this must be balanced with the central purpose of cascade testing; namely to 
promote autonomous decision-making by relatives about their genetic risk. This purpose 
would be hampered by inefficient or ineffective family communication processes. It is also 
important to recognise that the legal applicability of the two contact strategies may vary from 
country to country depending on legal rules and a particular country’s system of health care. 
For example, direct contact would not be possible in Norway, where privacy laws prevent 
physicians from contacting relatives who are not their patients.18 
Family contact represents standard practice in clinical genetics and some family linkage 
studies. If this method is used, a proband’s relatives may be less at risk of psychological harm 
through unsolicited contact. Their confidentiality is also protected. However, response rates 
using this method are likely to be lower. Given normal family contexts, information passed on 
to relatives from probands may have less impact than would an approach from a health 
professional. Or, probands may never ‘get around’ to contacting relatives. Direct contact 
tracing is less likely to encounter such problems and so more relatives are likely to present for 
screening. 
Below, we further explore the ethical tension between these two methods of contact. We 
argue that direct contact is ethically justifiable in the case of FH cascade screening, provided 
certain provisions are adhered to. Although the legal implications of unsolicited contact need 
to be borne in mind,19 we believe the risk that this will cause shock and anxiety can be 
managed and propose criteria to achieve this. 
 
Previous Cascade Screening Programmes 
We performed a systematic literature search to identify published studies involving cascade 
genetic screening and identify those that explicitly described the method of contact tracing 
employed and its psychosocial outcomes (see Table 1). Both family and direct contact have 
been employed, and discussion of these studies is divided into cascade screening for FH, and 
cascade screening for other genetic conditions. 
FH cascade screening: 
In the UK, FH cascade screening has been carried out on a small scale in two studies using 
direct contact tracing.15,20 In the first,20 each proband provided a family history, including 
contact details for first-degree relatives. Relatives were then sent a personalised standard 
letter explaining their at-risk status, the importance of this information and the options 
available. This approach was also used in the “GRAFT” study,15 however no data was available 
on relatives’ views about direct contact. 
A cascade screening study has been carried out in the Netherlands, although a DNA-based test 
was used.10,21 Direct contact tracing was employed, with probands consenting in writing to 
have their test results released to those first and second-degree relatives for whom contact 
information had been provided. The proband was also asked to inform his or her relatives 
about FH before they were approached by the clinical team. The psychological implications of 
the whole screening programme were investigated by interviewing over 600 relatives who had 
participated.21 Overall, 90% were satisfied with the method by which they were approached. 
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Additionally, 88% disagreed with the statement that it was improper to be approached 
without first being asked by a relative. 
In Norway, where direct contact is not possible under current laws, Tonstad et al asked 
probands to inform other family members about their diagnosis and need for screening (family 
contact tracing).18,22 However, the attitudes of probands towards FH screening supported 
direct contact. Of the 77% of relatives who were interested in testing, 74% wished to be 
informed directly by the proband’s physician, rather than by the proband.  
Cascade screening for other conditions: 
Cascade screening has also been undertaken for other conditions with a different mode of 
inheritance to FH. Although it has been reported that cascade testing is not an efficient 
method of population screening for autosomal recessive disorders,23 it is nonetheless relevant 
to examine these studies to discern participant’s attitudes towards the method of family 
tracing used. 
In Denmark, a cascade screening programme has been carried out for the recessive condition 
-1 Anti-trypsin deficiency.24,25 Direct contact was employed: after consenting to participate, 
the proband was asked to provide the names and contact details of relatives. The register 
wrote a letter to relatives summarising the condition and their risk.25 An examination of 
attitudes towards the method of relative contact indicated that 75% of probands would not 
rule out an unsolicited approach if it was difficult for the index case to inform relatives.25 
However, respondents felt that the proband should first be given the opportunity to inform 
relatives. Attitudes to approaching relatives also varied with factors such as the relative’s age, 
whether they have children and their emotional relationship with the proband.  
In assessing a cascade screening programme for the X-linked condition Duchenne Muscular 
Dystropy,26,27 Wright et al found that 98% of probands were happy to pass information on to 
relatives, and 78% thought it acceptable for risk information to be provided by the genetics 
service.26 If the proband was unable to discuss the condition with relatives but was happy for 
contact to be made, this was initiated via the relative’s GP, without disclosing the nature of the 
condition.26 In 51 interviews with at-risk relatives, none stated it was unacceptable for them to 
be proactively informed about their risk.27 Percentage acceptance of various methods of 
contact was very similar: 94% accepted being told by a family member, whilst 90% accepted 
being told by the genetics service. 
A cystic fibrosis cascade screening program has been run in Manchester for over 10 years, 
using family contact.20,28 After a family tree has been drawn up in conjunction with the clinical 
team, probands invited participation from their relatives through passing on a booklet 
describing CF and the opportunity for testing. Cascade screening has been generally well-
accepted, with uptake greater than expected; on average 20 additional tests were performed 
per family. 
Table 1: Summary of empirical investigations into Cascade Screening 
Country Study Disease Method 
Outcome of contact 
method? 
UK 
Bhatnagar et al 
(2000) 
FH Direct contact 
Not specifically 
addressed  
Holland 
van Maarle 
et al (2001) 
FH Direct contact  Proband informed 
relatives before direct 
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contact; 90% satisfaction 
UK 
Marteau et al 
(2004) 
FH Direct Contact 
Not specifically 
addressed  
Norway 
Tonstad et al 
(1995) 
FH Family contact 
Participants favoured 
direct contact 
Denmark 
Wilcke et al 
(1999) and 
(2000) 
-1 AT  Direct contact 
Direct contact acceptable 
so long as probands 
could contact relatives 
first 
UK 
Wright et al 
(2002); Kerzin-
Storrar et al 
(2002) 
DMD 
Family contact OR 
Direct contact 
Probands (78%) and 
relatives (90%) accepted 
clinic passing on 
information 
UK 
Super et al 
(1994); Roberts 
et al (2003) 
CF Family contact. 
Not specifically 
addressed but good 
uptake 
 
Direct contact: Ethical Issues 
The clinical investigation team, probands, relatives and society in general are likely to have 
varying interests and values with respect to cascade screening, which could give rise to 
tensions. For example, the investigation team’s motivation to promote health care within a 
wider group may conflict with the interests of relatives in maintaining privacy over their 
personal information. The ethical issues raised by direct contact tracing can be grouped into six 
main classes: 
1. Psychological harm to relatives.  
Arguably the greatest concern with direct contact in cascade testing is the potential for 
probands’ relatives to experience psychological harm. A relative who receives an unexpected 
letter containing serious medical information from a previously unknown clinical team could 
experience feelings of shock, anger and anxiety.25 In contacting relatives directly, an important 
checkpoint is removed: probands, who will tend to have good knowledge of the personality 
traits and dynamics present within their families. 
However, the actual risk of psychological harm through unsolicited contact may not be large. 
In a small study examining screening for several conditions, no relatives who had been 
approached directly experienced feelings of anger or annoyance.26 Indeed, probands’ relatives 
were virtually unanimous that the genetic risk knowledge was beneficial. Although half of the 
relatives did experience apprehension or anxiety, most also reported relief. Such initial 
concerns about health are a natural reaction to this information, and these are rarely long-
term in duration. 
This suggests that if the proband is first provided with general information to pass on to 
relatives, the potential for shock through unsolicited contact could be minimised. Probands 
could also be encouraged to informally discuss screening with relatives and alert the clinical 
team if there are any contextual family features which would warn against employing direct 
contact. 
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2. The right ‘not to know’. 
Related to concerns with psychological harm is the concern that directly contacting probands’ 
relatives will breach their right ‘not to know’ their health status.29 The putative right derives 
from respect for autonomy: the right to determine what we do and do not wish to know about 
our health. Directly providing a letter to relatives could be construed as a more significant 
breach of this right when compared to information being passed on by the proband. 
However, if the options for preventing the onset of disease are significant (as they are for FH), 
there is little reason to suppose that relatives would not be interested in this kind of 
information. Our biology doesn’t stop: the risk of developing CHD as a consequence of FH will 
still be present, even if relatives live in ignorance. Contrary to other conditions where the 
possibility of medically relevant interventions after pre-symptomatic testing is non-existent or 
minimal (such as Huntington’s Disease), there appears to be an ethical imperative to provide a 
choice. This is not to suggest that people should have unsolicited definitive risk information 
provided to them, but the right to remain in ignorance may not extend to the knowledge that 
a preventable genetic condition such as FH is present within one’s family. This contention is 
further supported by public health models, where individualistic ethical principles are 
subordinated in favour of acting beneficently towards the community as a whole.30  
This suggests, therefore, that relatives’ autonomy will be best respected by knowing that a risk 
is present and receiving assistance in coming to a decision about whether or not to undergo 
testing. The right ‘not to know’ about health status therefore has little impact upon the ethical 
standing of alternative methods of contact.  
3. Actual harm to relatives. 
In debates over genetic screening and testing, the potential for actual harm is often discussed. 
A person may be subject to discrimination or stigmatisation as a result of receiving genetic 
information. For example, one’s ability to obtain life insurance can be affected by a family 
history of disease, although in practice, the health questionnaire or medical examination 
required would usually identify the family history or the presence of hypercholesterolaemia. 
We have recently reported that most companies offer insurance to untreated FH patients at a 
higher premium, which is appropriate for a condition with a reduced life expectancy, but at a 
lower premium if the condition is well treated.31 The issue of a DNA based test result is not 
currently relevant since there is a UK moratorium (until late 2005) on using such genetic test 
results. 
However, cascade screening using direct contact instead of family contact will not raise the 
potential for discrimination, which is minimal in any case. Relatives will receive a generalised 
letter warning of an increased risk of the symptoms of FH, taking into account their family 
history. The effect of this letter will not be vastly different to that which would occur where a 
family member passes on the information. In both cases, a person who currently knows that 
he or she is at somewhat increased risk (for example having a parent who died of a heart 
attack) will not be in a substantially different position afterwards. Many relatives are already 
likely to realise that high cholesterol or CHD runs in their family, and this will be taken into 
account by insurers regardless of the information received via cascade screening. 
Direct contact will therefore not deny relatives the chance to make arrangements about life 
insurance. Risk status is only likely to change once an actual test result is received. 
4. A detrimental impact on family dynamics 
Relatives may feel aggrieved if a proband does not discuss his or her condition with them prior 
to an approach by the cascade project team. Introducing knowledge of a heritable condition 
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can draw out feelings of guilt and blame, particularly if existing relationships are strained. The 
nuances of intra-familial relationships must be taken into account when direct contact is being 
considered. Therefore, where direct contact is to be introduced, discussions should be held 
with the proband to determine the contextual features of his or her family’s structure, and 
potential difficulties arising from direct contact. If a proband reports any potential difficulties, 
alternative methods of approach should be used. Ideally, the clinical service should work with 
the proband to attain a tailored approach to family contact.32 
5. Breach of confidentiality 
Clinical care in genetic medicine is such that, in the majority of clinical consultations, 
information is collected about family members beyond the proband or consultand. Whilst this 
is generally considered as necessary for the provision of good clinical care, the recording of 
relatives’ contact details, in addition to their name, could be seen as a breach of relative’s 
confidentiality. The confidentiality of the proband’s health information may also be at risk.  
The issue of protecting relatives’ confidentiality will be difficult to overcome without 
introducing significant limitations to the process of direct contact. Although the proband could 
be asked to approach relatives to determine whether they would like to be contacted by the 
clinic, introducing this step will mean that many relatives will be lost to contact if the proband 
does not report back. We propose a compromise: relatives’ names and addresses should not 
be recorded in the cascade screening register until they have positively responded to contact. 
6. The potential for undue influence 
Using a clinical pretext when contacting relatives may lead relatives perceiving pressure to 
participate in screening, compelling them to undergo testing they may not otherwise have 
chosen. Van Maarle et al reported that relatives did perceive such pressure: 20% of 
participants felt as if the circumstances they were in more or less forced them to participate; 
and 63% agreed with the statement that they participated out of solidarity with their 
families.21 
However, just as the clinical veil is potentially problematic, so is family-initiated contact. A 
proband enrolled in cascade screening may engage in a ‘crusade’ to convince relatives to 
undergo testing, which could place them under more pressure than clinical contact ever 
would.  
The potential for undue influence should not, however, go unrecognised. Whilst active 
promotion of cascade screening is important to the programme’s success, clinical teams 
should ensure this is not taken beyond reasonable expectations for professionals in this area. 
Therefore, any materials sent directly to relatives should emphasise the voluntary nature of 
testing, and stipulate that non-participation will not prejudice the proband’s health care in any 
way. 
 
Advantages of direct contact 
The efficiency of cascade testing programmes 
How relatives are offered screening is likely to be a major determinant of uptake rates. Under 
direct contact, the number of relatives presenting for screening is likely to be significantly 
higher than if recruitment were left to probands. The overall cost-effectiveness of a cascade 
screening program is likely to be higher with direct contact, and a greater number of people 
will receive potentially life-saving health information and advice. Although no studies have 
been undertaken to directly compare these two methods of family tracing, other investigations 
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lend significant weight. For example, Sermijn et al recently reported that, in the context of 
Brca1/2 clinical testing, the “transfer of information from probands to their relatives is highly 
defective”33 and that a process of systematically informing relatives of mutation carriers is 
warranted. This process would be provided for if direct contact were adopted. 
This efficiency increase should, however, be balanced with the above ethical concerns and also 
broader concerns raised by the use of public health genetic models over individual clinical 
care.30 Concerns about privacy, stigmatisation and psychological harm should not be 
overridden to optimise a cascade screening programme. Therefore, efficiency should be 
considered a relevant factor in determining methods of relative contact, but it should not be 
the only consideration. Compromises may be necessary, such as providing a general leaflet to 
probands for distribution prior to relative contact. 
Increased accuracy of information 
Many relatives will already know of the presence of a condition like FH within their family, 
because one or several relatives will have had a heart attack, and this basic understanding may 
result in an increase in relatives’ desire to find out more.28 However, if probands were to 
contact relatives, the quality of the information they receive could deteriorate. Patients do not 
have perfect recall of information provided to them during counselling,34 and there are 
instances of incorrect information having being passed to family members.27 Even if written 
information is provided to the proband, they may fail to provide it to their relatives, instead 
giving their own account of the nature of the condition. By contrast if direct contact methods 
were employed, the clinic could ensure that all relatives received the same high-quality 
information.  
Again, however, accuracy alone should not be an overriding consideration in justifying direct 
contact. Indeed, employing good clinical follow-up with probands could ensure that written 
information is passed on. However, if information is clearly not being communicated, the clinic 
could ask the proband whether it would be better for them to contact relatives directly. 
Preventing harm to the proband 
Direct contact has a potential advantage of actually preventing harm to probands. It can be 
very difficult to discuss the risk of a heritable condition with family members. Probands may 
still be coming to terms with their own diagnosis, and may not feel ready for discussions with 
relatives. Direct contact can remove this burden by ‘professionalising’ the contact.  
 
An ethical ‘duty to warn’? 
For a variety of reasons, genetic risk information is not always disseminated throughout 
families. Families may not get along, or there be other complicating factors, such as a suspicion 
of non-paternity. Therefore, some probands will refuse to mediate any access to relatives. This 
is likely to be an uncommon occurrence and will often be resolvable through continuing 
discussion between the proband and the cascade testing team.26 Still, failures to provide 
relatives’ details have been described.20 This gives rise to a dilemma: if a proband refuses 
contact, should his or her confidentiality be breached in order to promote relatives’ 
autonomous decision-making? 
Much has been written in genetics about this ethical ‘duty to warn.’ For example, the Human 
Genetics Commission has concluded:35  
…disclosure of sensitive personal genetic information for the benefit of family 
members in certain circumstances may occasionally be justified. This would arise 
  9 
where a patient refuses to consent to such disclosure and the benefit of disclosure 
substantially outweighs the patient’s claim to confidentiality (at [3.68]). 
Other justifications for breaching confidentiality include the ‘right to know’ one’s genetic risks, 
the facilitation of relatives’ future decision-making, and the emerging argument that genetic 
information is ‘familial information’, not ‘individual information’.36 
For FH and other conditions where there is a proven intervention to prevent the onset of 
disease, the justification for breaching confidentiality in cascade testing may be stronger. 
However we also recognise that with 75% of probands still to be identified, a failure to warn of 
genetic risk could be overcome via other means, such as public education. The contact tracing 
protocol should foresee this issue and consider various alternative courses for action. 
Ultimately, any breach of confidentiality should only be considered when certain criteria are 
met, summarised in Table 2 
 
Table 2: Criteria to be met when breaching confidentiality is contemplated37 
(1) Identifiable relatives are at significant, foreseeable, quantifiable risk of a serious 
condition 
(2) Earlier intervention could reduce or alleviate serious harm 
(3) Harm from the failure to disclose must outweigh the harm caused by disclosure 
(4) Reasonable efforts to elicit disclosure fail after 2-3 meetings with proband 
(5) Alternative means of contacting the relative have been exhausted 
(6) Proband is briefed about the intention to breach confidentiality 
 
Conclusion 
Recommendation and practical strategy 
It may not be appropriate to straightforwardly and inflexibly adopt the direct contact method 
of family tracing for FH. This approach should not be taken at the expense of involving the 
proband, who should be given an adequate opportunity to communicate with his or her family 
members prior to contact being initiated by the cascade screening programme. 
We therefore propose that, rather than implementing direct contact tracing as soon as the 
proband has given permission for this to take place, it is preferable to do this only after initial 
family contact has been established by the proband, if they indicate their wish to do so. This 
renders the cascade screening programme a ‘second line’ of contact, but the main source of 
information, counselling and advice. This method of contact is flexible enough to allow families 
time for digestion and communication of information, yet will facilitate a greater rate of case 
identification. Probands will feel more empowered, yet will not have responsibility for 
following up all of their relatives. If a proband fails to respond to the clinic, a follow-up phone 
call can initiate direct contact. 
In developing a protocol for contacting relatives, several potential problems will need to be 
taken into consideration. The following recommendations should therefore be incorporated 
into protocol design:  
1. A nurse or doctor who has appropriate training should discuss the prospect of contact 
tracing with probands. 
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2. Probands should be provided with information to pass on to relatives before clinic contact. 
If no responses are received, contact the proband again to ask if clinic-initiated contact 
would be preferred. 
3. Direct contact with relatives should use general language to avoid reactions of alarm and 
concern. The voluntary nature of testing should be emphasised. 
4. Contact tracing should be tailored to each family by discussing aspects such as intra-
familial relationships and cultural factors with the proband. If a proband reports any 
potential difficulties, alternative methods of approach should be used. Contacting family 
members could be managed using the ‘Contextual Assessment Approach’ of Arar et al.32  
5. Do not record the names or addresses of relatives in the cascade screening register until 
they have positively responded to contact. 
6. Have detailed procedures for action to determine what to do if a proband refuses relative 
contact. 
A further ideal for the successful implementation of any contact tracing program is to 
appropriately and effectively monitor the impact of the tracing method in place, and to ensure 
a variety of ethnic groups are included in any studies which monitor quality of life and health 
outcomes following screening for genetic conditions. 
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